Ultragenyx Pharmaceutical Inc (RARE) : Iguana Healthcare Management scooped up 5,000 additional shares in Ultragenyx Pharmaceutical Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 120,000 shares of Ultragenyx Pharmaceutical Inc which is valued at $7,984,800.Ultragenyx Pharmaceutical Inc makes up approximately 3.14% of Iguana Healthcare Management’s portfolio.
Other Hedge Funds, Including , Capital Research Global Investors boosted its stake in RARE in the latest quarter, The investment management firm added 10,000 additional shares and now holds a total of 4,766,473 shares of Ultragenyx Pharmaceutical Inc which is valued at $317,161,113. Ultragenyx Pharmaceutical Inc makes up approx 0.10% of Capital Research Global Investors’s portfolio.Nuveen Asset Management boosted its stake in RARE in the latest quarter, The investment management firm added 5,331 additional shares and now holds a total of 22,679 shares of Ultragenyx Pharmaceutical Inc which is valued at $1,509,061. Ultragenyx Pharmaceutical Inc makes up approx 0.01% of Nuveen Asset Management’s portfolio.Columbia Partners L L C Investment Management reduced its stake in RARE by selling 31,504 shares or 84.27% in the most recent quarter. The Hedge Fund company now holds 5,882 shares of RARE which is valued at $391,388. Ultragenyx Pharmaceutical Inc makes up approx 0.03% of Columbia Partners L L C Investment Management’s portfolio.Blackrock Fund Advisors reduced its stake in RARE by selling 51,866 shares or 3.59% in the most recent quarter. The Hedge Fund company now holds 1,390,985 shares of RARE which is valued at $92,556,142. Ultragenyx Pharmaceutical Inc makes up approx 0.02% of Blackrock Fund Advisors’s portfolio.Jennison Associates reduced its stake in RARE by selling 86,706 shares or 14.83% in the most recent quarter. The Hedge Fund company now holds 498,041 shares of RARE which is valued at $32,392,587. Ultragenyx Pharmaceutical Inc makes up approx 0.03% of Jennison Associates’s portfolio.
Ultragenyx Pharmaceutical Inc opened for trading at $66.26 and hit $66.72 on the upside on Thursday, eventually ending the session at $66.275, with a gain of 0.54% or 0.355 points. The heightened volatility saw the trading volume jump to 2,80,763 shares. Company has a market cap of $2,614 M.
On the company’s financial health, Ultragenyx Pharmaceutical Inc reported $-1.46 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-1.44.During the same quarter in the previous year, the company posted $-0.83 EPS.
Many Wall Street Analysts have commented on Ultragenyx Pharmaceutical Inc. Piper Jaffray Initiated Ultragenyx Pharmaceutical Inc on Jul 7, 2016 to “Overweight”, Price Target of the shares are set at $70.Ultragenyx Pharmaceutical Inc was Initiated by BofA/Merrill to “Buy” on Jun 28, 2016.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).